Genetic modulation of plasma fibrinogen concentrations: Possible importance of interleukin-6

Maurizio Margaglione, Elvira Grandone, Francesco Paolo Mancini, Giovanni Di Minno

Research output: Contribution to journalArticle

Abstract

Current knowledge indicates that high plasma levels of fibrinogen, a key protein in the hemostatic system, help predict the major ischemic complications of atherosclerosis, that is, stroke and myocardial infarction. Molecular variations at the fibrinogen genes loci have been shown to regulate fibrinogen concentrations in plasma. However, it is also known that fibrinogen is an acute phase reactant and that its plasma levels are increased by the inflammatory mediator interleukin 6 (IL-6) as a consequence of stimulated gene expression. Certain risk factors for atherosclerosis are known to cause inflammatory and proliferative events within the vessel wall, especially when combined. This raises the question of whether and to what extent high plasma fibrinogen levels in patients with major thrombotic complications of atherosclerosis could be the epiphenomena of as yet poorly elucidated issues in vascular medicine (i.e., severity of vascular damage). Screening of the fibrinogen genes loci in both young patients with established risk factors and in patients evaluated for regression of atherosclerosis who have participated in risk factor reduction programs may provide further insight into the role of genetic factors in the development of atherosclerosis and in the regulation of plasma fibrinogen levels.

Original languageEnglish
Pages (from-to)51-56
Number of pages6
JournalJournal of Thrombosis and Thrombolysis
Volume3
Issue number1
Publication statusPublished - 1996

Fingerprint

Fibrinogen
Interleukin-6
Atherosclerosis
Acute-Phase Proteins
Hemostatics
Risk Reduction Behavior
Cardiology
Genes
Blood Vessels
Stroke
Myocardial Infarction
Gene Expression
Proteins

Keywords

  • Fibrinogen
  • Genetic modulation
  • Interleukin-6

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Hematology

Cite this

Genetic modulation of plasma fibrinogen concentrations : Possible importance of interleukin-6. / Margaglione, Maurizio; Grandone, Elvira; Mancini, Francesco Paolo; Di Minno, Giovanni.

In: Journal of Thrombosis and Thrombolysis, Vol. 3, No. 1, 1996, p. 51-56.

Research output: Contribution to journalArticle

Margaglione, Maurizio ; Grandone, Elvira ; Mancini, Francesco Paolo ; Di Minno, Giovanni. / Genetic modulation of plasma fibrinogen concentrations : Possible importance of interleukin-6. In: Journal of Thrombosis and Thrombolysis. 1996 ; Vol. 3, No. 1. pp. 51-56.
@article{39217467809b4f05918a2d446611e1f4,
title = "Genetic modulation of plasma fibrinogen concentrations: Possible importance of interleukin-6",
abstract = "Current knowledge indicates that high plasma levels of fibrinogen, a key protein in the hemostatic system, help predict the major ischemic complications of atherosclerosis, that is, stroke and myocardial infarction. Molecular variations at the fibrinogen genes loci have been shown to regulate fibrinogen concentrations in plasma. However, it is also known that fibrinogen is an acute phase reactant and that its plasma levels are increased by the inflammatory mediator interleukin 6 (IL-6) as a consequence of stimulated gene expression. Certain risk factors for atherosclerosis are known to cause inflammatory and proliferative events within the vessel wall, especially when combined. This raises the question of whether and to what extent high plasma fibrinogen levels in patients with major thrombotic complications of atherosclerosis could be the epiphenomena of as yet poorly elucidated issues in vascular medicine (i.e., severity of vascular damage). Screening of the fibrinogen genes loci in both young patients with established risk factors and in patients evaluated for regression of atherosclerosis who have participated in risk factor reduction programs may provide further insight into the role of genetic factors in the development of atherosclerosis and in the regulation of plasma fibrinogen levels.",
keywords = "Fibrinogen, Genetic modulation, Interleukin-6",
author = "Maurizio Margaglione and Elvira Grandone and Mancini, {Francesco Paolo} and {Di Minno}, Giovanni",
year = "1996",
language = "English",
volume = "3",
pages = "51--56",
journal = "Journal of Thrombosis and Thrombolysis",
issn = "0929-5305",
publisher = "Springer Netherlands",
number = "1",

}

TY - JOUR

T1 - Genetic modulation of plasma fibrinogen concentrations

T2 - Possible importance of interleukin-6

AU - Margaglione, Maurizio

AU - Grandone, Elvira

AU - Mancini, Francesco Paolo

AU - Di Minno, Giovanni

PY - 1996

Y1 - 1996

N2 - Current knowledge indicates that high plasma levels of fibrinogen, a key protein in the hemostatic system, help predict the major ischemic complications of atherosclerosis, that is, stroke and myocardial infarction. Molecular variations at the fibrinogen genes loci have been shown to regulate fibrinogen concentrations in plasma. However, it is also known that fibrinogen is an acute phase reactant and that its plasma levels are increased by the inflammatory mediator interleukin 6 (IL-6) as a consequence of stimulated gene expression. Certain risk factors for atherosclerosis are known to cause inflammatory and proliferative events within the vessel wall, especially when combined. This raises the question of whether and to what extent high plasma fibrinogen levels in patients with major thrombotic complications of atherosclerosis could be the epiphenomena of as yet poorly elucidated issues in vascular medicine (i.e., severity of vascular damage). Screening of the fibrinogen genes loci in both young patients with established risk factors and in patients evaluated for regression of atherosclerosis who have participated in risk factor reduction programs may provide further insight into the role of genetic factors in the development of atherosclerosis and in the regulation of plasma fibrinogen levels.

AB - Current knowledge indicates that high plasma levels of fibrinogen, a key protein in the hemostatic system, help predict the major ischemic complications of atherosclerosis, that is, stroke and myocardial infarction. Molecular variations at the fibrinogen genes loci have been shown to regulate fibrinogen concentrations in plasma. However, it is also known that fibrinogen is an acute phase reactant and that its plasma levels are increased by the inflammatory mediator interleukin 6 (IL-6) as a consequence of stimulated gene expression. Certain risk factors for atherosclerosis are known to cause inflammatory and proliferative events within the vessel wall, especially when combined. This raises the question of whether and to what extent high plasma fibrinogen levels in patients with major thrombotic complications of atherosclerosis could be the epiphenomena of as yet poorly elucidated issues in vascular medicine (i.e., severity of vascular damage). Screening of the fibrinogen genes loci in both young patients with established risk factors and in patients evaluated for regression of atherosclerosis who have participated in risk factor reduction programs may provide further insight into the role of genetic factors in the development of atherosclerosis and in the regulation of plasma fibrinogen levels.

KW - Fibrinogen

KW - Genetic modulation

KW - Interleukin-6

UR - http://www.scopus.com/inward/record.url?scp=0029877123&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029877123&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0029877123

VL - 3

SP - 51

EP - 56

JO - Journal of Thrombosis and Thrombolysis

JF - Journal of Thrombosis and Thrombolysis

SN - 0929-5305

IS - 1

ER -